Trial Profile
Long-term impact of eculizumab on quality of life and patient-reported symptoms of Japanese GBS patients at 52 weeks post disease onset: an observational survey
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary) ; Immune globulin
- Indications Guillain-Barre syndrome
- Focus Therapeutic Use
- Acronyms ECU-GBS-LTO
- Sponsors Alexion AstraZeneca Rare Disease
- 23 Jun 2022 New trial record